Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations.

Daouk R, Hassane M, Bahmad HF, Sinjab A, Fujimoto J, Abou-Kheir W, Kadara H.

Front Oncol. 2019 Apr 2;9:207. doi: 10.3389/fonc.2019.00207. eCollection 2019.

2.

Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung.

Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P.

EBioMedicine. 2019 Apr;42:296-303. doi: 10.1016/j.ebiom.2019.03.020. Epub 2019 Mar 21.

3.

Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P.

Am J Respir Crit Care Med. 2019 Mar 21. doi: 10.1164/rccm.201806-1178OC. [Epub ahead of print]

PMID:
30896962
4.

Epigenetic Suppression of the T-box Subfamily 2 (TBX2) in Human Non-Small Cell Lung Cancer.

Nehme E, Rahal Z, Sinjab A, Khalil A, Chami H, Nemer G, Kadara H.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1159. doi: 10.3390/ijms20051159.

5.

Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes.

Khalil A, Dekmak B, Boulos F, Kantrowitz J, Spira A, Fujimoto J, Kadara H, El-Hachem N, Nemer G.

Front Oncol. 2018 Oct 30;8:482. doi: 10.3389/fonc.2018.00482. eCollection 2018.

6.

Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.

Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ.

Nat Commun. 2018 Nov 2;9(1):4589. doi: 10.1038/s41467-018-07042-y.

7.

Genomics of adult and pediatric solid tumors.

Rahal Z, Abdulhai F, Kadara H, Saab R.

Am J Cancer Res. 2018 Aug 1;8(8):1356-1386. eCollection 2018. Review.

8.

Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.

Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N, Azzegagh Z, Hara NM, Ehre C, Mohebnasab M, Caetano MS, Merrick DT, van Bokhoven A, Wistuba II, Kadara H, Dickey BF, Velmurugan K, Mann PR, Lu X, Barón AE, Evans CM, Moghaddam SJ.

JCI Insight. 2018 Aug 9;3(15). pii: 120941. doi: 10.1172/jci.insight.120941. eCollection 2018 Aug 9.

9.

IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.

Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez BA, Evans SE, Hanash S, Alekseev AM, Yang Y, Chang SH, Nurieva R, Kadara H, Chen J, Ostrin EJ, Moghaddam SJ.

Cancer Immunol Res. 2018 Jul;6(7):788-797. doi: 10.1158/2326-6066.CIR-17-0655. Epub 2018 May 15.

PMID:
29764837
10.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2018 Apr 1;29(4):1072. doi: 10.1093/annonc/mdx062. No abstract available.

PMID:
29688333
11.

Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase α.

Abdel-Samad R, Aouad P, Gali-Muhtasib H, Sweidan Z, Hmadi R, Kadara H, D'Andrea EL, Fucci A, Pisano C, Darwiche N.

Am J Cancer Res. 2018 Jan 1;8(1):39-55. eCollection 2018.

12.

Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma.

Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H.

Cancer Prev Res (Phila). 2018 Apr;11(4):237-248. doi: 10.1158/1940-6207.CAPR-17-0295. Epub 2018 Jan 30.

13.

Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform.

Deshpande A, Lang W, McDowell T, Sivakumar S, Zhang J, Wang J, San Lucas FA, Fowler J, Kadara H, Scheet P.

BMC Bioinformatics. 2018 Jan 4;19(1):5. doi: 10.1186/s12859-017-1991-3.

14.

SLURP-1 is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene.

Bergqvist C, Kadara H, Hamie L, Nemer G, Safi R, Karouni M, Marrouche N, Abbas O, Hasbani DJ, Kibbi AG, Nassar D, Shimomura Y, Kurban M.

Int J Dermatol. 2018 Feb;57(2):162-170. doi: 10.1111/ijd.13850. Epub 2017 Dec 12.

PMID:
29231248
15.

microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis.

Nassar FJ, Talhouk R, Zgheib NK, Tfayli A, El Sabban M, El Saghir NS, Boulos F, Jabbour MN, Chalala C, Boustany RM, Kadara H, Zhang Z, Zheng Y, Joyce B, Hou L, Bazarbachi A, Calin G, Nasr R.

Sci Rep. 2017 Dec 4;7(1):16829. doi: 10.1038/s41598-017-16978-y.

16.

Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR; Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium.

Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.

17.

Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria.

Bazzi S, El-Darzi E, McDowell T, Modjtahedi H, Mudan S, Achkar M, Akle C, Kadara H, Bahr GM.

Front Immunol. 2017 Oct 3;8:1253. doi: 10.3389/fimmu.2017.01253. eCollection 2017.

18.

TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection.

Khalil AA, Sivakumar S, Lucas FAS, McDowell T, Lang W, Tabata K, Fujimoto J, Yatabe Y, Spira A, Scheet P, Nemer G, Kadara H.

Oncotarget. 2017 Aug 4;8(40):68230-68241. doi: 10.18632/oncotarget.19938. eCollection 2017 Sep 15.

19.

Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H.

Cancer Res. 2017 Nov 15;77(22):6119-6130. doi: 10.1158/0008-5472.CAN-17-1605. Epub 2017 Sep 26.

20.

Smoking and Lung Cancer: A Geo-Regional Perspective.

Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H.

Front Oncol. 2017 Sep 1;7:194. doi: 10.3389/fonc.2017.00194. eCollection 2017. Review.

21.

Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.

Fujimoto J, Nunomura-Nakamura S, Liu Y, Lang W, McDowell T, Jakubek Y, Ezzeddine D, Kapere Ochieng J, Petersen J, Davies G, Fukuoka J, Wistuba II, Ehli E, Fowler J, Scheet P, Kadara H.

Int J Cancer. 2017 Oct 15;141(8):1589-1599. doi: 10.1002/ijc.30851. Epub 2017 Jul 17.

22.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV.

Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30.

23.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II.

Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437.

24.

Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer.

Kadara H, Nemer G, Safi R, Rebeiz N, Daou L, Delbani D, Btadini W, Abbas O, Tofaili M, Bitar F, Kibbi AG, Shimomura Y, Kurban M.

Clin Genet. 2017 Nov;92(5):495-502. doi: 10.1111/cge.12968. Epub 2017 Aug 2.

PMID:
28075030
25.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436.

26.

Radiotherapeutic bandage for the treatment of squamous cell carcinoma of the skin.

Koneru B, Shi Y, Munaweera I, Wight-Carter M, Kadara H, Yuan H, Di Pasqua AJ, Balkus KJ Jr.

Nucl Med Biol. 2016 Jun;43(6):333-8. doi: 10.1016/j.nucmedbio.2016.02.010. Epub 2016 Mar 17.

27.

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. Epub 2016 Jun 1.

28.

Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway.

Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H.

Cancer Res. 2016 Jul 1;76(13):3676-83. doi: 10.1158/0008-5472.CAN-15-3064. Epub 2016 May 23.

29.

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, Behrens C, Wistuba II, Sternberg C, Kadara H, Ferreira CG, Watowich SS, Moghaddam SJ.

Cancer Res. 2016 Jun 1;76(11):3189-99. doi: 10.1158/0008-5472.CAN-15-2840. Epub 2016 Apr 1.

30.

Early Events in the Molecular Pathogenesis of Lung Cancer.

Kadara H, Scheet P, Wistuba II, Spira AE.

Cancer Prev Res (Phila). 2016 Jul;9(7):518-27. doi: 10.1158/1940-6207.CAPR-15-0400. Epub 2016 Mar 22. Review.

31.

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.

Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM.

Oncotarget. 2016 Jan 5;7(1):565-79. doi: 10.18632/oncotarget.6376.

32.

LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells.

Maki Y, Fujimoto J, Lang W, Xu L, Behrens C, Wistuba II, Kadara H.

Sci Rep. 2015 Sep 7;5:13846. doi: 10.1038/srep13846.

33.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

34.

Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer.

Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II.

J Natl Cancer Inst. 2014 Mar;106(3):dju004. doi: 10.1093/jnci/dju004. Epub 2014 Feb 22.

35.

Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.

Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK.

Clin Cancer Res. 2014 Apr 1;20(7):1946-54. doi: 10.1158/1078-0432.CCR-13-1959. Epub 2013 Dec 23.

36.

EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.

Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II.

Clin Cancer Res. 2013 Dec 1;19(23):6556-65. doi: 10.1158/1078-0432.CCR-12-3946. Epub 2013 Oct 4.

37.

ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.

Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H.

Clin Cancer Res. 2013 Jul 1;19(13):3383-95. doi: 10.1158/1078-0432.CCR-13-0341. Epub 2013 May 9.

38.

G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.

Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II.

J Thorac Oncol. 2012 Dec;7(12):1747-1754. doi: 10.1097/JTO.0b013e31826bb1ff.

39.

Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II.

Cancer Prev Res (Phila). 2013 Jan;6(1):8-17. doi: 10.1158/1940-6207.CAPR-12-0290. Epub 2012 Oct 19.

40.

High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II.

J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

41.

Field cancerization in non-small cell lung cancer: implications in disease pathogenesis.

Kadara H, Wistuba II.

Proc Am Thorac Soc. 2012 May;9(2):38-42. doi: 10.1513/pats.201201-004MS.

42.

Reuben Lotan, Ph.D. (1946-2011): in memoriam.

Kadara H.

Cancer Biol Ther. 2011 Dec 15;12(12):1015-7. doi: 10.4161/cbt.12.12.18841. Epub 2011 Dec 15. No abstract available.

PMID:
22236874
43.

Pulmonary adenocarcinoma: a renewed entity in 2011.

Kadara H, Kabbout M, Wistuba II.

Respirology. 2012 Jan;17(1):50-65. doi: 10.1111/j.1440-1843.2011.02095.x. Review.

44.

Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome.

Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA.

Cancer. 2012 Jun 1;118(11):2889-99. doi: 10.1002/cncr.26584. Epub 2011 Oct 21.

45.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV.

J Clin Invest. 2011 Apr;121(4):1313-28. doi: 10.1172/JCI42405. Epub 2011 Mar 23.

46.

Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.

Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II.

Clin Cancer Res. 2011 Apr 15;17(8):2434-43. doi: 10.1158/1078-0432.CCR-10-1412. Epub 2011 Jan 21.

47.

A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.

Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R.

Clin Cancer Res. 2011 Mar 15;17(6):1490-501. doi: 10.1158/1078-0432.CCR-10-2703. Epub 2010 Dec 16.

48.

Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor.

Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, Lotan R.

Cancer Res. 2010 Nov 1;70(21):8917-26. doi: 10.1158/0008-5472.CAN-10-0518. Epub 2010 Oct 19.

49.

Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice.

Fujimoto J, Kadara H, Men T, van Pelt C, Lotan D, Lotan R.

PLoS One. 2010 Jul 29;5(7):e11847. doi: 10.1371/journal.pone.0011847.

50.

Supplemental Content

Loading ...
Support Center